Hepatic Origin Or Derivative Patents (Class 435/370)
  • Patent number: 10073096
    Abstract: Provided herein are compositions, methods and uses that relate to or result from the identification of markers that can distinguish between cells at different stages of pluripotency. Certain embodiments provide markers that can distinguish between parental cells (i.e. differentiated cells), partially pluripotent (i.e. partially reprogrammed) and pluripotent (i.e. fully reprogrammed cells). Also provided here are uses of such differential markers, for example, in identification of cell potential, in diagnostics, in differential separation, and in creating efficient workflows that involve fewer steps and lesser time in identifying or separating a desired reprogrammed clone or cell line from a mixture of cells at various stages of pluripotency. In certain embodiments, the activity of these markers can be manipulated to influence cell potential for research or medical purposes.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: September 11, 2018
    Assignee: Life Technologies Corporation
    Inventors: Uma Lakshmipathy, Rene Quintanilla, Joanna Asprer
  • Patent number: 9790470
    Abstract: This invention relates to the in vitro differentiation of pluripotent cells into pancreatic progenitors by i) culturing pluripotent cells in a definitive endoderm (DE) medium comprising a TGFp ligand, fibroblast growth factor (FGF), bone morphogenetic protein (BMP), a PI3K inhibitor and optionally a GSK3 ? inhibitor to produce a population of definitive endoderm cells, ii) culturing the definitive endoderm cells in a first pancreatic medium comprising an activin antagonist; FGF; retinoic acid; and a BMP inhibitor to produce a population of dorsal foregut cells; iii) culturing the dorsal foregut cells in a second pancreatic medium comprising FGF, retinoic acid, a BMP inhibitor, and a hedgehog signalling inhibitor, and; iv) culturing the endoderm cells in a third pancreatic medium comprising FGF. The progenitor cells thus produced may be further differentiated into pancreatic endocrine cells. These methods may be useful, for example, in producing pancreatic cells for therapy or disease modelling.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: October 17, 2017
    Assignee: Cambridge Enterprise Limited
    Inventors: Ludovic Vallier, Hsin-hua Cho
  • Patent number: 9771409
    Abstract: The present invention discloses cryopreserved recombinant cells for screening drug candidates that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. Advantageously, such cells provide a cost-efficient consumable product that streamlines the process of screening whether drug candidates are substrates or inhibitors of drug transporter proteins and/or drug metabolizing enzymes.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: September 26, 2017
    Assignee: Corning Incorporated
    Inventors: Na Li, Jie Wang, Christopher J. Patten
  • Patent number: 9765301
    Abstract: The invention relates to a liver organoid, uses thereof and method for obtaining them.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: September 19, 2017
    Assignee: Koninklijke Nederlandse Akademie van Wetenschappen
    Inventors: Meritxell Huch Ortega, Johannes Carolus Clevers
  • Patent number: 9750770
    Abstract: A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated. The graft consists of stem cells or progenitors that are admixed with biomaterials and, optionally, with cytokines and/or native epithelial-mesenchymal cells appropriate for the maturational lineage stage of the cells to be engrafted.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: September 5, 2017
    Assignees: The University of North Carolina at Chapel Hill, University of Miami-Diabetes Research Institute, Sapienza Università Di Roma
    Inventors: Lola M. Reid, Yunfang Wang, David A. Gerber, Giacomo Lanzoni, Luca Inverardi, Juan Dominguez-Bendala, Domenico Alvaro, Vincenzo Cardinale, Eugenio Gaudio, Guido Carpino
  • Patent number: 9371515
    Abstract: The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: June 21, 2016
    Assignee: Bone Therapeutics S.A.
    Inventors: Cindy Badoer, Enrico Bastianelli, Xavier Pesesse
  • Patent number: 9347953
    Abstract: The present invention relates to a method for diagnosing a carcinoma or a residual disease associated thereto, or for the prognosis of a carcinoma, or for monitoring the effectiveness of an anti-tumour therapy directed against a carcinoma, or for monitoring the follow-up of an individual affected by a carcinoma, in particular colorectal carcinoma, carcinoma of the stomach, mammary carcinoma, pulmonary carcinoma or carcinoma of the prostate, carcinoma of the liver, carcinoma of the ovary, carcinoma of the kidney, carcinoma of the thyroid, carcinoma of the bladder or carcinoma of the pancreas. The method of the invention consists in placing adult stem cells in contact with a sample of a haemo-derivative of the individual to be analyzed and in verifying the expression of at least an epithelial marker in the stem cells by means of immunofluorescence, immunohistochemistry, ELISA or RT-PCR.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: May 24, 2016
    Assignee: THD S.p.A.
    Inventors: Filippo Bastia, Donato Altomare, Alfredo Di Leo, Maria Teresa Rotelli, Michele Barone
  • Patent number: 9341550
    Abstract: Conventional CTC detection methods have been problematic in that 1) there is no technique for automatically determining and counting live CTCs in a brief period of time, 2) no process has been developed for detecting, counting, and thereafter collecting and culturing live CTCs, and 3) there exists no flow cytometer that is contamination free and is capable of measuring an entire sample. Provided is a CTC detection method which comprises a pre-treatment step for concentrating and fluorescence staining CTCs, and a step for identifying and counting CTCs. The pre-treatment step includes attaching magnetic beads to EpCAM antibodies expressed by epithelial cell-derived CTCs and concentrating the CTCs through the use of a magnet, fluorescently labeling an epithelia cell surface marker of the CTCs through the use of EpCAM antibodies or 5E11 antibodies, and performing two types of nuclear staining, one being cell membrane-permeable and the other being cell membrane-impermeable.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: May 17, 2016
    Assignee: ON-CHIP BIOTECHNOLOGIES CO., LTD.
    Inventors: Kazuo Takeda, Fumie Jimma, Masashi Takao
  • Patent number: 9057053
    Abstract: Methods, compositions and kits for producing functional neurons, astroctyes, oligodendrocytes and progenitor cells thereof are provided. These methods, compositions and kits find use in producing neurons, astrocytes, oligodendrocytes, and progenitor cells thereof for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the CNS. Also provided are methods, compositions and kits for screening candidate agents for activity in converting cells into neuronal cells, astrocytes, oligodendrocytes, and progenitor cells thereof.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: June 16, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Marius Wernig, Thomas C. Sudhof, Thomas Vierbuchen, Austin Ostermeier, Zhiping Pang
  • Publication number: 20150139953
    Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 21, 2015
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Publication number: 20150132853
    Abstract: Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.
    Type: Application
    Filed: June 11, 2014
    Publication date: May 14, 2015
    Applicant: Advanced Cell Technology, Inc.
    Inventor: Karen B. Chapman
  • Publication number: 20150094450
    Abstract: The present invention relates to an repebody capable of binding specifically to interleukin-6 (IL-6) to inhibit the biological activity of IL-6, a polynucleotide encoding the repebody, a vector comprising the polynucleotide, a recombinant microorganism having introduced therein the polynucleotide or the vector, a method of producing the repebody using the recombinant microorganism, a composition for preventing or treating cancer, which comprises the repebody, and a method for preventing or treating cancer, which comprises administering the composition for preventing or treating cancer, which comprises the repebody. The repebody of the present invention significantly reduces the activity of STAT3 and the concentration of interleukin-6, and thus can be widely used as an agent for preventing or treating IL-6-related diseases.
    Type: Application
    Filed: February 27, 2013
    Publication date: April 2, 2015
    Applicants: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC), KOREA BASIC SCIENCE INSTITUTE
    Inventors: Hak-Sung Kim, Joong-Jae Lee, Jung Min Choi, Eun-Kyeong Jo, Chul-Su Yang, Hae-Kap Cheong, Hyun Jung Kim
  • Publication number: 20150072418
    Abstract: Replicons of genotype 4d hepatitis C virus (HCV) are provided. These replicons contain adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 4d replicons and methods of using these replicons to screen antiviral agents are also provided.
    Type: Application
    Filed: August 14, 2014
    Publication date: March 12, 2015
    Inventors: HADAS DVORY-SOBOL, CHRISTY HEBNER, HONGMEI MO, SIMIN XU
  • Publication number: 20150073389
    Abstract: Human hepatocyte cell cultures and their use in bioreactors and bioartificial liver (BAL) systems are provided. The cells have constitutive liver-specific metabolic activity resembling that of freshly isolated human hepatocytes. The hepatocyte cells and BAL systems can be used to treat patients suffering from acute liver failure, end-stage liver disease, or acute-on-chronic liver disease.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 12, 2015
    Applicant: Academisch Ziekenhuis Bij De Universiteit Van Amsterdam
    Inventors: Robert Antoine Francois Marie CHAMULEAU, Ruurdtje HOEKSTRA, Gerardus Adrianus Antonius NIBOURG
  • Publication number: 20150072353
    Abstract: Analyte sensors, methods for producing and using analyte sensors, methods of detecting and/or measuring analyte activity, detecting pH change, and/or, controlling the concentration of an analyte in a system, are disclosed. Embodiments of the analyte sensors according to the disclosure can provide an accurate and convenient method for characterizing analyte activity, detecting pH change, controlling the concentration of an analyte in a system, and the like, in both in vivo and in vitro environments, in particular in living cell imaging.
    Type: Application
    Filed: August 21, 2014
    Publication date: March 12, 2015
    Inventors: Jenny Jie Yang, Shen Tang
  • Publication number: 20150071883
    Abstract: The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.
    Type: Application
    Filed: September 10, 2014
    Publication date: March 12, 2015
    Inventor: Peter Cameron Colosi
  • Publication number: 20150064789
    Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases. Also described are methods of making and using compositions comprising these linkers.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 5, 2015
    Inventors: David Paschon, Lei Zhang
  • Publication number: 20150065560
    Abstract: The present invention relates to a one-vector expression system comprising a sequence encoding two polypeptides, such as tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1 (GCH1). The two polypeptides can be should preferentially be expressed at a ratio between 3:1 and 15:1, such as between 3:1 and 7:1. The invention is useful in the treatment of catecholamine deficient disorders, such as dopamine deficient disorders including but not limited to Parkinson's Disease. Moreover, the present invention provides a method to deliver the vector construct in order to limit the increased production of the catecholamine to the cells in need thereof.
    Type: Application
    Filed: April 1, 2014
    Publication date: March 5, 2015
    Inventors: Tomas Björklund, Anders Björklund, Deniz Kirik
  • Publication number: 20150044768
    Abstract: The method of the invention provides for producing a heterologous protein in mammalian host cells having nucleic acid encoding Hepatitis B X protein and the heterologous protein, by growing mammalian host cells selected from the group consistng of HKB11, CHO, BHK21, C2C12, and HEK293 cells, by growing mammalian host cells in non-adherent suspension culture, or by growing mammalian host cells which contain nucleic acid providing exogenous X-box Binding Protein, XBP1s. The conditions should be such that HBx, exogenous XBP1s if present, and the heterologous protein are expressed by the mammalian cells. The invention includes compositions for carrying out the method.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventors: FANG JIN, RICHARD N. HARKINS, MAXINE BAUZON, TERRY HERMISTON
  • Publication number: 20150030574
    Abstract: The present invention relates generally to a population of cells genetically modified to produce insulin in a glucose responsive manner and uses thereof. More particularly, the present invention relates to a population of cells genetically modified to produce insulin in response to physiologically relevant levels of glucose and uses thereof. The cells of the present invention are useful in a wide variety of applications, in particular in the context of therapeutic and prophylactic regimes directed to the treatment of diabetes and/or the amelioration of symptoms associated with diabetes, based on the transplantation of the cells of the present invention into mammals requiring treatment. Also facilitated is the design of in vitro based screening systems for testing the therapeutic effectiveness and/or toxicity of potential adjunctive treatment regimes.
    Type: Application
    Filed: February 20, 2014
    Publication date: January 29, 2015
    Applicant: University of Technology, Sydney
    Inventors: Ann Margaret Simpson, Chang Tao
  • Publication number: 20150005369
    Abstract: Disclosed are methods of gene delivery using capsid-modified recombinant adeno-associated viral (rAAV) vectors. Exemplary methods are provided employing vectors that have altered affinity for heparin or heparin sulfate, as well as vectors, expression systems, and rAAV virions that lack functional VP2 protein expression, but are nevertheless, fully virulent. Also provided by the invention are methods employing the rAAV vector-based compositions, virus particles, host cells, and pharmaceutical formulations in the expression of selected therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in selected mammals, including organs, tissues, and human host cells.
    Type: Application
    Filed: July 8, 2014
    Publication date: January 1, 2015
    Inventors: Nicholas Muzyczka, Shaun R. Opie, Kenneth H. Warrington
  • Publication number: 20150004690
    Abstract: The invention describes novel virus-like particles for use as vaccines, diagnostic tools and R&D tools based on recombinant DNA and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. These epitopes are then displayed on the particle surface.
    Type: Application
    Filed: August 29, 2014
    Publication date: January 1, 2015
    Inventors: Corinne JOHN, Christian SCHAUB, Sabine WELLNITZ
  • Patent number: 8920793
    Abstract: The present invention relates to the preparation of poly(amino oxalate) (PAOX) using oxalyl chloride, 1,4-cyclohexanedimethanol, and piperazinediethanol, the preparation of biodegradable polymer particles using the PAOX, and the use of PAOX particles as a drug delivery vehicle. The PAOX according to the present invention is a polymer that has three characteristics of biodegradability, biocompatibility, and cationic properties at the same time with appropriate hydrophobicity and thus can be prepared as particles that allow rapid drug release. Moreover, the particles improve the delivery efficiency of a drug into cells and thus can be efficiently used as a drug delivery vehicle for the treatment of acute inflammatory diseases such as acute liver failure and acute lung injury.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: December 30, 2014
    Assignee: Industrial Cooperation Foundation Chonbuk National University
    Inventors: Dong Won Lee, Kyeong Yeol Seong, Han Sol Seo, Hyung Min Kim, Ye Rang Kim
  • Publication number: 20140377862
    Abstract: Provided is a cell cultivation method in which the cell is cultured using a peptide hydrogel as a scaffold, for carrying out high-dimensional culture of a cell such as porcine hepatocyte, human hepatocyte, porcine pancreatic islet or human pancreatic islet for a long period under conditions where cell survival, cell morphology and cell functions are maintained. Also provided are a cell culture including a cell and a peptide hydrogel obtained by the above-described cultivation method, a bioreactor including the cell culture, and a cell preparation including the cell culture.
    Type: Application
    Filed: January 6, 2014
    Publication date: December 25, 2014
    Applicants: 3-D Matrix, Ltd., National University Corporation Okayama University
    Inventors: Naoya KOBAYASHI, Noriaki TANAKA
  • Publication number: 20140363810
    Abstract: A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.
    Type: Application
    Filed: August 25, 2014
    Publication date: December 11, 2014
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Yasushi YAMAZOE, Kiyoshi NAGATA
  • Publication number: 20140363473
    Abstract: The present invention relates to a method for preparing spheroids of human primary hepatocytes. The method comprises culturing of isolated human primary hepatocytes on a polysaccharide scaffold under conditions that allow the formation of hepatocyte spheroids, and subsequently dissolving the polysaccharide scaffold to release the hepatocyte spheroids. The spheroids obtained by the method of the invention are particularly suitable for being transplanted into a subject afflicted with a liver disease.
    Type: Application
    Filed: December 14, 2012
    Publication date: December 11, 2014
    Inventors: Jörg-Matthias Pollok, Jeanette Bierwolf
  • Publication number: 20140356960
    Abstract: The present invention relates to a nucleic acid containing at least one homing endonuclease site (HE) and at least one restriction enzyme site (X) wherein the HE and X sites are selected such that HE and X result in compatible cohesive ends when cut by the homing endonuclease and restriction enzyme, respectively, and the ligation product of HE and X cohesive ends can neither be cleaved by the homing endonuclease nor by the restriction enzyme. Further subject-matter of the present invention relates to a vector comprising the nucleic acid of the present invention, host cells containing the nucleic acid and/or the vector; a kit for cloning and/or expression of multiprotein complexes making use of the vector and the host cells, a method for producing a vector containing multiple expression cassettes, and a method for producing multiprotein complexes.
    Type: Application
    Filed: April 25, 2014
    Publication date: December 4, 2014
    Inventor: Imre Berger
  • Publication number: 20140356951
    Abstract: This document provides methods and materials related to differentiating iPS cells into glucose-responsive, insulin-secreting progeny. For example, methods and material for using indolactam V (ILV) and glucagon like peptide-1 (GLP-1) to produce glucose-responsive, insulin-secreting progeny from iPS cells are provided.
    Type: Application
    Filed: July 24, 2014
    Publication date: December 4, 2014
    Inventors: Tayaramma Thatava, Andre Terzic, Yogish C. Kudva, Yasuhiro Ikeda
  • Patent number: 8889848
    Abstract: Replicons of genotype 3 of hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 3 replicons and methods of using these replicons to screen antiviral agents are also provided.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: November 18, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: William E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Mei Yu, Amoreena Corsa
  • Patent number: 8889849
    Abstract: Replicons of genotype 4 hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 4 replicons and methods of using these replicons to screen antiviral agents are also provided.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: November 18, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: William E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Betty Peng
  • Publication number: 20140322704
    Abstract: The invention relates to the discovery that DHH derived from stem cells are permissive for infection by hepatitis viruses (HV), such as hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV) and hepatitis E virus (HEV). Included in the invention are HV-permissive DHHs and methods of making an HCV-permissive DHH derived from a stem cell. Also included is an HV culture system comprising at least one HV-permissive DHH. The HV-permissive DHH and HV culture system are useful for conducting HV life cycle analyses, diagnosing a subject as being infected with HV, genotyping and characterizing the HV of a subject infected with HV, detecting drug resistance of HV obtained from a subject infected with HV, screening for and identify modulators of HV infection, and monitoring the effect of a treatment of HV in a subject.
    Type: Application
    Filed: December 19, 2012
    Publication date: October 30, 2014
    Inventors: Hengli Tang, Xianfang Wu
  • Publication number: 20140322184
    Abstract: The invention relates to an expression cassette including a gene of interest under the control of an inducible promoter, characterized in that said inducible promoter includes at least one CARE regulatory sequence (C/EBP-ATF responsive element) and a minimal promoter. The invention also relates to a vector and a host cell, as well as to a pharmaceutical composition including such a cassette, and to the use thereof for treating diseases by gene therapy.
    Type: Application
    Filed: November 6, 2012
    Publication date: October 30, 2014
    Inventors: Pierre Farfournoux, Alain Bruhat, Celine Jousse, Anne-Catherine Maurin, Julien Averous
  • Publication number: 20140315804
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 23, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
  • Publication number: 20140315835
    Abstract: The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 23, 2014
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Kallanthottathil G. Rajeev, Tracy Zimmermann, Muthiah Manoharan, Martin Maier, Satyanarayana Kuchimanchi, Klaus Charisse
  • Patent number: 8865465
    Abstract: Synthetic cell culture surfaces, including a hydrophobe modified cellulose or an hydroxylated acrylate polymer composition and optionally including a silica source, cell culture coating and cell culture articles incorporating the composition, and methods of making and using the articles for cell culture, as defined herein.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: October 21, 2014
    Assignee: Corning Incorporated
    Inventors: Wendy Annette Baker, Theresa Chang, Robert Randall Hancock, Jr.
  • Publication number: 20140310830
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Application
    Filed: December 12, 2013
    Publication date: October 16, 2014
    Inventors: Feng ZHANG, Le CONG, Fei RAN
  • Patent number: 8858934
    Abstract: The present invention relates to a method of producing cells having at least one characteristic of human hepatocytes as well as to cells produced by said method and uses of these cells.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: October 14, 2014
    Assignee: ABAG Verwaltungs GmbH
    Inventors: Alexander Gerbes, Andreas Benesic
  • Publication number: 20140302092
    Abstract: A nucleic acid includes the 5? untranslated region, a virus protein-coding region including the NS3 protein coding sequence, the NS4A protein coding sequence, the NS4B protein coding sequence, the NS5A protein coding sequence, and the NS5B protein coding sequence, and the 3? untranslated region of the HCV J6CF genome in that order from the 5? to 3? direction. The NS4A protein coding sequence has a mutation for substituting alanine at position 1680 with glutamic acid, as determined on the basis of the amino acid sequence of the precursor protein of the J6CF strain.
    Type: Application
    Filed: May 31, 2012
    Publication date: October 9, 2014
    Applicants: Toray Industries, Inc., Japan as Represented by Director-General of National Institute of Infectious Diseases
    Inventors: Takaji Wakita, Asako Murayama, Takanobu Kato
  • Publication number: 20140302601
    Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.
    Type: Application
    Filed: April 3, 2014
    Publication date: October 9, 2014
    Applicants: University of North Carolina at Chapel Hill, Vesta Therapeutics Inc.
    Inventors: Lola M. REID, Nicholas MOSS, Mark E. FURTH, John W. LUDLOW, Andrew T. BRUCE
  • Publication number: 20140302547
    Abstract: A method of obtaining a mixture of cells enriched in hepatic progenitors is developed which comprises methods yielding suspensions of a mixture of cell types, and selecting those cells that are classical MHC class I antigen(s) negative and ICAM-1 antigen positive. The weak or dull expression of nonclassical MHC class I antigen(s) can be used for further enrichment of hepatic progenitors. Furthermore, the progenitors can be selected to have a level of side scatter, a measure of granularity or cytoplasmic droplets, that is higher than that in non-parenchymal cells, such as hemopoietic cells, and lower than that in mature parenchymal cells, such as hepatocytes. Furthermore, the progeny of the isolated progenitors can express alpha-fetoprotein and/or albumin and/or CK19. The hepatic progenitors, so isolated, can grow clonally, that is an entire population of progeny can be derived from one cell. The clones of progenitors have a growth pattern in culture of piled-up aggregates or clusters.
    Type: Application
    Filed: April 3, 2014
    Publication date: October 9, 2014
    Applicant: University of North Carolina at Chapel Hill
    Inventors: HIROSHI KUBOTA, Lola M. Reid
  • Publication number: 20140302082
    Abstract: A subgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and a fullgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and infectious HCV particle-producing ability, each derived from a novel HCV of genotype 1b, are provided. Particularly, a subgenomic replicon RNA (nucleic acid) and a fullgenomic replicon RNA (nucleic acid), each derived from an HCV genome of the NC1 strain which is a novel HCV genotype 1b isolated from a patient with acute severe hepatitis C, are provided.
    Type: Application
    Filed: March 30, 2012
    Publication date: October 9, 2014
    Applicants: JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASE, PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, TORAY INDUSTRIES, INC.
    Inventors: Takaji Wakita, Tomoko Date, Yasuhito Tanaka, Masashi Mizokami
  • Publication number: 20140295548
    Abstract: A bioartificial liver system is described that incorporates a cell reservoir and hepatocyte spheroids to both increase the number of and longevity of cells in the system. Additional methods are also described for forming spheroid aggregates from isolated hepatocytes.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventor: Scott L. Nyberg
  • Publication number: 20140295544
    Abstract: The present invention relates to fluorescent proteins, in particular green fluorescent proteins (GFPs), with increased activity in cells, and thus increased signal strength. A further aspect of the present invention relates to the use of peptides for increasing the expression and/or stability of a protein in a cell.
    Type: Application
    Filed: June 13, 2014
    Publication date: October 2, 2014
    Inventor: Khalid S. Abu KHABAR
  • Patent number: 8846891
    Abstract: The present inventors used the previously developed H77/JFH 1T27OOC,A4O8OT (1a/2a), J4/JFH 1T2996C,A4827T,?HVRI (1b/2a), J6/JFH 1?HVRI (2a/2a), J8/JFH 1?HVRI (2b/2a), S52/JFH 1T27i8G,?7i6oc (3a/2a), SA13/JFH 1C34O5G,A3696G (5a/2a) and HK6a/JFH 1T1389c,A1590G (6a/2a) constructs for the deletion of Hypervariable Region 1 (HVR1) to construct viable, JFH 1 (genotype 2a) based, genomes. The present inventors serially passaged the viruses in cell culture obtaining relatively high HCV RNA titers and infectivity titers. Sequence analysis of the viruses identified mutations adapting H77/JFH 1T27OOC,A4O8OT,?HVR1 (1a/2a), J8/JFH 1?HVR1 (2b/2a), S52/JFH 1T2718G,T716OC,?HVR1 (3a/2a) and J4/JFH 1T2996C,A4827T,?HVR1 (1b/2a) to the HVR1 deletion.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: September 30, 2014
    Assignees: Hvidovre Hospital, Kobenhavns Universitet
    Inventors: Jannick Prento, Judith M. Gottwein, Troels Kasper Hoyer Scheel, Tanja Bertelsen Jensen, Jens Bukh
  • Publication number: 20140286995
    Abstract: A nucleic acid includes, in the following order, a 5? untranslated region comprising a particular nucleotide sequence of the genome of hepatitis C virus genotype 3a; a nucleotide sequence encoding a particular amino acid sequence of an NS3 protein, a nucleotide sequence encoding a particular amino acid sequence of an NS4A protein, a nucleotide sequence encoding a particular amino acid sequence of an NS4B protein, a nucleotide sequence encoding a particular amino acid sequence of an NS5A protein, a nucleotide sequence encoding a particular amino acid sequence of an NS5B protein of the hepatitis C virus genotype 3a; and a 3? untranslated region comprising a particular nucleotide sequence of a genome of hepatitis C virus genotype 3a.
    Type: Application
    Filed: August 31, 2012
    Publication date: September 25, 2014
    Applicants: Japan as Represented by Director-General of National Institute of Infectious Diseases, Toray Industries, Inc., INSERM Institutut National de la Sante et de la Recherche Medicale
    Inventors: Takaji Wakita, Mohsan Saeed, Patrick Maurel, Claire Gondeau, Hiroshi Yokokawa
  • Publication number: 20140286917
    Abstract: Isolated liver progenitor stem cells and cell populations of isolated liver progenitor stem cells are disclosed. The progenitor stem cells originate from adult liver, especially human adult liver. The isolated progenitor stem cells have uses in medicine, hepatology, inborn errors of liver metabolism transplantation, infectious diseases and liver failure. Methods of isolating these cells and their culture is described. The isolated cells are characterized before and after differentiation. Their use for transplantation and as animal models of human disease, toxicology and pharmacology is disclosed.
    Type: Application
    Filed: June 3, 2014
    Publication date: September 25, 2014
    Applicant: Universite Catholique de Louvain
    Inventors: Etienne Sokal, Mustapha Najimi
  • Publication number: 20140274782
    Abstract: Methyl-lysine affinity reagents created by engineering the 3×MBT methyl-lysine binding domain repeat of lethal (3) malignant brain tumor-like protein 1 (L3MBTL1) are disclosed. In particular, the invention relates to affinity reagents and affinity chromatography media comprising the 3×MBT domain repeat and methods of using such affinity reagents in detection, purification, and proteomic profiling of methylated proteins and peptides.
    Type: Application
    Filed: March 15, 2014
    Publication date: September 18, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Scott M. Carlson, Or Gozani, Kaitlyn E. Moore
  • Publication number: 20140272932
    Abstract: The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.
    Type: Application
    Filed: December 23, 2013
    Publication date: September 18, 2014
    Applicant: Abbott Laboratories
    Inventors: A. Scott Muerhoff, Christopher Marohnic, Larry Birkenmeyer, John Prostko, Felisha Bogdan, Robin Gutierrez
  • Publication number: 20140235693
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpinal gene, and methods of using such dsRNA compositions to inhibit expression of Serpinal. In one embodiment, an iRNA for inhibiting expression of a Serpinal gene includes at least two sequences that are complementary to each other. The iRNA includes a sense strand having a first sequence and an antisense strand having a second sequence. The antisense strand includes a nucleotide sequence that is substantially complementary to at least part of an mRNA encoding Serpinal, and the region of complementarity is 30 nucleotides or less, and at least 15 nucleotides in length. Generally, the iRNA is 19 to 24, e.g., 19 to 21 nucleotides in length.
    Type: Application
    Filed: June 22, 2012
    Publication date: August 21, 2014
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt
  • Publication number: 20140237631
    Abstract: Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof.
    Type: Application
    Filed: March 31, 2014
    Publication date: August 21, 2014
    Applicants: KIMRON VETERINARY INSTITUTE, INSTITUT PASTEUR
    Inventors: Despres Philippe, Vincent Deubel, Jean-Louis Guenet, Marie-Therese Drouet, Mertyn Malkinson, Caroline Banet, Marie-Pascale Frenkiel, Marie-Pierre Courageot, Fasseli Coulibaly, Adeline Catteau, Marie Flamand, Patrick Weber, Pierre-Emmanuel Ceccaldi